News Image

NASDAQ:PCRX is an undervalued gem with solid fundamentals.

By Mill Chart

Last update: Jan 19, 2024

Our stock screener has spotted PACIRA BIOSCIENCES INC (NASDAQ:PCRX) as an undervalued stock with solid fundamentals. NASDAQ:PCRX shows decent health and profitability. At the same time it remains remains attractively priced. We'll dive into each aspect below.

Looking at the Valuation

ChartMill provides a Valuation Rating to every stock, ranging from 0 to 10. This rating assesses various valuation aspects, comparing price to earnings and cash flows, while considering factors like profitability and growth. NASDAQ:PCRX boasts a 8 out of 10:

  • PCRX is valuated reasonably with a Price/Earnings ratio of 11.21.
  • 89.60% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of PCRX to the average of the S&P500 Index (25.64), we can say PCRX is valued rather cheaply.
  • The Price/Forward Earnings ratio is 9.03, which indicates a very decent valuation of PCRX.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 91.58% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of PCRX to the average of the S&P500 Index (20.61), we can say PCRX is valued rather cheaply.
  • 87.13% of the companies in the same industry are more expensive than PCRX, based on the Enterprise Value to EBITDA ratio.
  • 91.58% of the companies in the same industry are more expensive than PCRX, based on the Price/Free Cash Flow ratio.
  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PCRX has a very decent profitability rating, which may justify a higher PE ratio.
  • PCRX's earnings are expected to grow with 18.44% in the coming years. This may justify a more expensive valuation.

A Closer Look at Profitability for NASDAQ:PCRX

ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:PCRX scores a 7 out of 10:

  • Looking at the Return On Assets, with a value of 0.46%, PCRX belongs to the top of the industry, outperforming 81.68% of the companies in the same industry.
  • PCRX has a better Return On Equity (0.85%) than 82.18% of its industry peers.
  • The Return On Invested Capital of PCRX (3.49%) is better than 82.18% of its industry peers.
  • Looking at the Profit Margin, with a value of 1.07%, PCRX belongs to the top of the industry, outperforming 82.18% of the companies in the same industry.
  • PCRX's Operating Margin of 10.15% is amongst the best of the industry. PCRX outperforms 83.17% of its industry peers.
  • PCRX's Operating Margin has improved in the last couple of years.
  • PCRX has a better Gross Margin (70.12%) than 77.72% of its industry peers.

Analyzing Health Metrics

ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NASDAQ:PCRX scores a 6 out of 10:

  • PCRX has a better Altman-Z score (1.99) than 69.31% of its industry peers.
  • With an excellent Debt to FCF ratio value of 4.03, PCRX belongs to the best of the industry, outperforming 88.61% of the companies in the same industry.
  • A Current Ratio of 4.77 indicates that PCRX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.77, PCRX is in the better half of the industry, outperforming 60.89% of the companies in the same industry.
  • PCRX has a Quick Ratio of 3.74. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.

A Closer Look at Growth for NASDAQ:PCRX

ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:PCRX has earned a 5 for growth:

  • Measured over the past years, PCRX shows a very strong growth in Earnings Per Share. The EPS has been growing by 68.62% on average per year.
  • Measured over the past years, PCRX shows a quite strong growth in Revenue. The Revenue has been growing by 18.40% on average per year.
  • Based on estimates for the next years, PCRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.13% on average per year.

More Decent Value stocks can be found in our Decent Value screener.

Our latest full fundamental report of PCRX contains the most current fundamental analsysis.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (5/17/2024, 7:19:04 PM)

After market: 30.82 0 (0%)

30.82

-0.69 (-2.19%)

PCRX News

News Image22 hours ago - Market News VideoJuly 19th Options Now Available For Pacira BioSciences (PCRX)
News Image3 days ago - ChartmillWhen you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

When you look at PACIRA BIOSCIENCES INC (NASDAQ:PCRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

News Image4 days ago - Market News VideoPacira BioSciences (PCRX) Shares Cross Above 200 DMA
News Image8 days ago - Pacira BioSciencesPacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
News Image10 days ago - Pacira BioSciencesPacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
News Image10 days ago - Pacira BioSciencesPacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and...

News Image11 days ago - InvestorPlacePCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024

PCRX stock results show that Pacira BioSciences met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

News Image11 days ago - BusinessInsiderPCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pacira BioSciences (NASDAQ:PCRX) just reported results for the first quarter of...

News Image11 days ago - Pacira BioSciencesPacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
News Image11 days ago - Pacira BioSciencesPacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program

-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader...

News Image11 days ago - Pacira BioSciencesPacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
News Image11 days ago - Pacira BioSciencesPacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside...

PCRX Links
Follow us for more